"AULSS 21 Mater Salutis"
Welcome,         Profile    Billing    Logout  
 11 Trials 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bonetti, Andrea
EDOI, NCT04072068 / 2018-003833-14: Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy

Recruiting
4
300
Europe
Edoxaban
Gruppo Oncologico Italiano di Ricerca Clinica, Daiichi Sankyo Italia S.p.A.
Thromboembolism, Cancer
01/21
01/22
TAILOR, NCT00637910 / 2007-004786-17: Tarceva Italian Lung Optimization tRial

Checkmark KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
Checkmark WCLC 2013
Checkmark ECCO-ESMO-ESTRO 2013
Checkmark Erlotinib vs. docetaxel as s2nd-line treatment in pts with adv NSCLC & wild-type EGFR tumors
Checkmark P3 data
More
Recruiting
3
850
Europe
Erlotinib, Tarceva, Docetaxel, Taxotere
Fatebenefratelli and Ophthalmic Hospital, Mario Negri Institute for Pharmacological Research, Niguarda Hospital
Non Small Cell Lung Cancer (NSCLC)
02/12
02/13
ZEAL-1L, NCT04475939 / 2020-002202-20: Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer

Checkmark [VIRTUAL] First-line (1L Maintenance Therapy with Niraparib (nira + Pembrolizumab (pembro vs Placebo + Pembro in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC: Phase 3 ZEAL-1L Study
Checkmark JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Checkmark [VIRTUAL] First-line (1L) maintenance therapy with niraparib (nira) + pembrolizumab (pembro) vs placebo + pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
Checkmark Niraparib (Nira) + pembrolizumab (Pembro) versus placebo (PBO) + Pembro 1L maintenance therapy in advanced non-small cell lung cancer (NSCLC): ZEAL-1L phase 3 study
Recruiting
3
650
Europe, US, RoW
Niraparib, Pembrolizumab, Placebo
GlaxoSmithKline
Lung Cancer, Non-Small Cell
08/24
10/24
eMonarcHER, NCT04752332 / 2020-004035-24: A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer

Checkmark [VIRTUAL] eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
Recruiting
3
2450
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Standard Adjuvant ET, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms
05/25
02/33
Nabster, NCT03219762 / 2016-000408-27: Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC

Checkmark Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
Checkmark Phase II study of NAB-paclitaxel in SensiTivE and Refractory relapsed SCLC (NABSTER TRIAL)
Recruiting
2
65
Europe
Nabpaclitaxel, Abraxane
Gruppo Oncologico Italiano di Ricerca Clinica, Temas srl, Clirest s.r.l., Mipharm S.p.A., Istituto Toscano Tumori - Centro per il Coordinamento delle Sperimentazioni Cliniche
Small Cell Lung Cancer
01/19
01/19
CHENDO, NCT03227328 / 2016-004107-31: CDK4/6-inhibitor or Chemotherapy, in Combination With ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

Recruiting
2
150
Europe
concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy, chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Agenzia Italiana del Farmaco
Hormone Receptor Positive Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Negative Breast Cancer
02/22
07/22
CeLEBrATE, NCT04730999 / 2019-003798-25: Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer

Recruiting
2
52
Europe
Etoposide, Carboplatin, Bevacizumab, Atezolizumab
Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma, Italy, YGHEA, CRO Division of Ecol Studio spa, Dr. Luca Boni U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino - IST NORD CBA
Small Cell Lung Cancer
06/23
10/24
EORTC 1745-ETF-BCG, NCT03609047 / 2018-002553-30: Adjuvant Palbociclib in Elderly Patients With Breast Cancer

Recruiting
2
366
Europe, RoW
Palbociclib, Docetaxel / cyclophosphamide, doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, paclitaxel
European Organisation for Research and Treatment of Cancer - EORTC, Pfizer, Swedish Association of Breast Oncologists, International Breast Cancer Study Group, German Adjuvant Breast Cancer Group, SOLTI Breast Cancer Research Group, UNICANCER, Gruppo Oncologico Italiano di Ricerca Clinica
Breast Cancer Stage II, Breast Cancer Stage III
06/25
06/32
NCT03818464: Psychological Assessment Before General Anesthesia (VeSPPA2018)

Not yet recruiting
N/A
100
Europe
University of Parma
Anesthesia
02/20
03/21
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4000
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
NCT04810182: Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Recruiting
N/A
150
Europe
Regorafenib 40 MG Oral Tablet [STIVARGA]
Istituto Oncologico Veneto IRCCS
Glioblastoma Multiforme
08/22
08/22

Download Options